Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Non-Current Liabilities (2016 - 2026)

Summit Therapeutics filings provide 13 years of Total Non-Current Liabilities readings, the most recent being $100.1 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 164.99% to $100.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $100.1 million through Mar 2026, up 164.99% year-over-year, with the annual reading at $90.5 million for FY2025, 100.28% up from the prior year.
  • Total Non-Current Liabilities hit $100.1 million in Q1 2026 for Summit Therapeutics, up from $90.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $536.1 million in Q4 2022 and bottomed at $19.7 million in Q3 2022.
  • Average Total Non-Current Liabilities over 5 years is $109.8 million, with a median of $90.5 million recorded in 2025.
  • The largest annual shift saw Total Non-Current Liabilities surged 1862.67% in 2022 before it tumbled 76.93% in 2023.
  • Summit Therapeutics' Total Non-Current Liabilities stood at $536.1 million in 2022, then crashed by 76.93% to $123.7 million in 2023, then tumbled by 63.47% to $45.2 million in 2024, then surged by 100.28% to $90.5 million in 2025, then grew by 10.65% to $100.1 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Total Non-Current Liabilities are $100.1 million (Q1 2026), $90.5 million (Q4 2025), and $67.6 million (Q3 2025).